29.44MMarket Cap-795P/E (TTM)
1.040High0.920Low320.68KVolume0.929Open0.885Pre Close315.32KTurnover1.22%Turnover RatioLossP/E (Static)30.35MShares5.07052wk High3.14P/B25.43MFloat Cap0.52052wk Low--Dividend TTM26.21MShs Float39.390Historical High--Div YieldTTM13.56%Amplitude0.520Historical Low0.983Avg Price1Lot Size
Neuronetics Stock Forum
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
Neuronetics, Inc. (NASDAQ: STIM) announced its participation at the American Academy of Child and Adolescent Psychiatry (AACAP) conference in Seattle, WA, from October 14th-19th. The company will present data on the NeuroStar TMS System in an oral presentation at the 'Research Pipeline: New Findings on Therapeutics' session. This presentation will ...
Health Care Service Corporation Adds First-Line TMS Coverage for AdolescentsNeuronetics, Inc. (NASDAQ: STIM) announced that Health Care Service (HCSC) has expanded access to TMS (transcranial magnetic stimulation) for adolescents 15 and older with major depressive disorder (MDD). This policy update aligns with the recent FDA clearance of NeuroStar TMS Therapy as a first-line add-on treatment for this age group. HCSC, the largest customer-owned health insurer in the U.S...
3 MINUTES AGO, 8:31 AM EDT
VIA GLOBENEWSWIRE
MALVERN, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that additional payors have updated their TMS (transcranial magnetic stimulation) cove...
NeuroStar® Releases Software Upgrades to Elevate Patient Care
Neuronetics (NASDAQ: STIM) has announced significant upgrades to its NeuroStar Advanced Therapy and TrakStar® patient data management software. The enhancements focus on improving patient communication, streamlining clinical data capture, and strengthening cybersecurity. Key upgrades include:
1. Enhanced Patient Communication: New CRM capabilities for automated SMS and email communication, secure insurance ...
Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge
Neuronetics (NASDAQ: STIM) and Greenbrook TMS (OTCMKTS: GBNHF) have announced a definitive agreement to merge in an all-stock transaction. The merger aims to create a vertically-integrated organization providing TMS therapy with significant scale. Key benefits include:
1. Increased brand awareness for NeuroStar TMS
2. More consistent delivery of best practices
3. Enhanced benefits for all NeuroStar c...
Neuronetics: Aetna Updated Tms Coverage to Include Adolescents Aged 15 and Older With
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
Neuronetics announced its participation in the 12th Annual Clinical TMS Society (CTMSS) Meeting in London from June 13-15, 2024. They will present six posters and one oral presentation showcasing data from the NeuroStar TMS System. Highlights include early prediction of nonresponse in major depressive disorder, the impact of treatment timing, efficacy of accelerated TMS protocols, effect...
No comment yet